These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35620200)

  • 1. Evaluation of synergism in drug combinations and reference models for future orientations in oncology.
    Duarte D; Vale N
    Curr Res Pharmacol Drug Discov; 2022; 3():100110. PubMed ID: 35620200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput Flow Cytometry Drug Combination Discovery with Novel Synergy Analysis Software, SynScreen.
    Perez DR; Edwards BS; Sklar LA; Chigaev A
    SLAS Discov; 2018 Aug; 23(7):751-760. PubMed ID: 29842834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
    Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
    Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical formulation of additivity for antimicrobial agents.
    Boucher AN; Tam VH
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):319-25. PubMed ID: 16626903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of drug combinations: current methodological landscape.
    Foucquier J; Guedj M
    Pharmacol Res Perspect; 2015 Jun; 3(3):e00149. PubMed ID: 26171228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology.
    El Hassouni B; Mantini G; Li Petri G; Capula M; Boyd L; Weinstein HNW; Vallés-Marti A; Kouwenhoven MCM; Giovannetti E; Westerman BA; Peters GJ;
    Anticancer Res; 2019 Jul; 39(7):3303-3309. PubMed ID: 31262850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple test for synergy for a small number of combinations.
    Novick SJ
    Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Effect of Mycotoxin Combinations: Which Mathematical Model Is (the Most) Appropriate?
    Kifer D; Jakšić D; Šegvić Klarić M
    Toxins (Basel); 2020 Feb; 12(3):. PubMed ID: 32121330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additivity of inhibitory effects in multidrug combinations.
    Russ D; Kishony R
    Nat Microbiol; 2018 Dec; 3(12):1339-1345. PubMed ID: 30323252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacodynamic model of clinical synergy in multiple myeloma.
    Sudalagunta P; Silva MC; Canevarolo RR; Alugubelli RR; DeAvila G; Tungesvik A; Perez L; Gatenby R; Gillies R; Baz R; Meads MB; Shain KH; Silva AS
    EBioMedicine; 2020 Apr; 54():102716. PubMed ID: 32268267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additivity and Interactions in Ecotoxicity of Pollutant Mixtures: Some Patterns, Conclusions, and Open Questions.
    Rodea-Palomares I; González-Pleiter M; Martín-Betancor K; Rosal R; Fernández-Piñas F
    Toxics; 2015 Sep; 3(4):342-369. PubMed ID: 29051468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs.
    Novotný B; Nagy M; Kurin E
    Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of drug interactions.
    Bijnsdorp IV; Giovannetti E; Peters GJ
    Methods Mol Biol; 2011; 731():421-34. PubMed ID: 21516426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs).
    Wild M; Kicuntod J; Seyler L; Wangen C; Bertzbach LD; Conradie AM; Kaufer BB; Wagner S; Michel D; Eickhoff J; Tsogoeva SB; Bäuerle T; Hahn F; Marschall M
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico drug combination discovery for personalized cancer therapy.
    Jeon M; Kim S; Park S; Lee H; Kang J
    BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents.
    Tam VH; Schilling AN; Lewis RE; Melnick DA; Boucher AN
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4315-21. PubMed ID: 15504858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.